Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference

by Barry101 | Jan 23, 2019 | Press Release

OCALA, Fla., Jan. 23, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that CEO Thomas K. Equels will present at...

Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center

by Barry101 | Jan 8, 2019 | Press Release

The Phase II Study Will Combine Hemispherx’s Ampligen with KeytrudaOCALA, Fla., Jan. 08, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology,...

Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

by Barry101 | Jan 2, 2019 | Press Release

Second Large Shipment Dispatched to Second Major ClinicOCALA, Fla., Jan. 02, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 325...

Hemispherx Biopharma Issues Business Update to Clarify Apple iOS12 Stocks Application ‘No Recent Stories’ Misinformation

by Barry101 | Dec 26, 2018 | Press Release

OCALA, Fla., Dec. 26, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) continues to work with Apple and other affected parties for a solution to correct Apple iOS12 Stocks Application misinformation and enable investors using the Apple device for their...

Hemispherx Biopharma Inc. Announces First Large Ampligen Shipment to a Clinical Site for Use in U.S. Expanded Access Program

by Barry101 | Dec 19, 2018 | Press Release

OCALA, Fla., Dec. 19, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, shipped 720 vials of Ampligen to the Myalgic Encephalomyelitis/Chronic...

Hemispherx Biopharma Inc. Announces Updated Information about ME/CFS Expanded Access Program in the United States

by Barry101 | Dec 17, 2018 | Press Release

Highlights Include Visit with Patients in North CarolinaOCALA, Fla., Dec. 17, 2018 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, recently met with...